Benzinga · Aug 25, 2026
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
AN
NASDAQ · ANAB
AnaptysBio, Inc.
Healthcare · Biotechnology
$57.46
Down-$0.66 (-1.15%)
Updated Sep 4, 2026, 10:00 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.52B
- P/E ratio
- -18.91
- Dividend yield
- 0.00%
- 52-week range
- $17.11 – $73.30
- Volume
- 366.85K
- Avg. volume
- 462.18K
Price performance
ANAB price history
1M range · 21 trading sessions · Daily adjusted prices
ANAB closed at $57.46 after 21 trading sessions, up 4.91% for the selected period.
- Last close
- $57.46
- Period change
- +4.91%
- Period low
- $54.77
- Period high
- $59.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $56.33 | $57.77 | $55.00 | $57.46 | 366.85K |
| Sep 2, 2026 | $56.13 | $57.90 | $54.66 | $55.84 | 421.73K |
| Sep 1, 2026 | $56.82 | $58.09 | $54.84 | $55.28 | 773.86K |
| Aug 31, 2026 | $55.83 | $57.22 | $55.00 | $57.03 | 332.17K |
| Aug 28, 2026 | $57.24 | $57.24 | $55.375 | $56.28 | 358.57K |
| Aug 27, 2026 | $58.03 | $58.43 | $57.101 | $57.29 | 533.74K |
| Aug 26, 2026 | $58.27 | $58.86 | $57.365 | $58.00 | 210.37K |
| Aug 25, 2026 | $58.09 | $58.99 | $56.805 | $58.37 | 341.84K |
| Aug 24, 2026 | $56.96 | $59.065 | $55.565 | $58.44 | 627.05K |
| Aug 21, 2026 | $57.23 | $58.78 | $56.62 | $57.74 | 318.37K |
| Aug 20, 2026 | $58.52 | $59.69 | $56.33 | $56.69 | 389.39K |
| Aug 19, 2026 | $60.31 | $60.31 | $58.43 | $59.26 | 258.75K |
| Aug 18, 2026 | $58.90 | $60.02 | $58.16 | $58.99 | 260.45K |
| Aug 17, 2026 | $57.78 | $59.885 | $57.485 | $59.69 | 255.84K |
| Aug 14, 2026 | $56.00 | $58.54 | $55.30 | $58.47 | 330.89K |
| Aug 13, 2026 | $57.07 | $57.65 | $55.60 | $56.02 | 270.91K |
| Aug 12, 2026 | $57.99 | $58.11 | $56.64 | $56.98 | 381.73K |
| Aug 11, 2026 | $56.79 | $59.00 | $56.41 | $57.87 | 372.05K |
| Aug 10, 2026 | $56.56 | $58.86 | $55.315 | $55.47 | 419.58K |
| Aug 7, 2026 | $55.20 | $57.38 | $55.13 | $56.61 | 546.73K |
| Aug 6, 2026 | $55.28 | $56.0656 | $53.45 | $54.77 | 289.06K |
Latest ANAB news
The latest Smart Investors Daily articles mentioning ANAB.
Stock researchCompany · Overview
ANAB research
Overview
Company profile and research snapshot.
Company profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $54.20
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | UBS | Buy | — |
| May 13, 2026 | Barclays | Overweight | — |
| May 4, 2026 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 24, 2026
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
ChartMill · Aug 19, 2026
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup
AnaptysBio (ANAB) combines high growth momentum with strong technicals and a breakout setup. Learn about its ratings, metrics, and risks.
SeekingAlpha · Jul 29, 2026
AnaptysBio: The Royalty Waterfall Is About To Reverse
AnaptysBio (ANAB) stock shifts to a lean royalty company tied to GSKâs Jemperli. Jemperli royalties escalate with sales. Read here for a detailed analysis.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
